Changing face of pulmonary arterial hypertension in Canada

References

• Wood P. Pulmonary hypertension. Br Med Bull. 1952;8:348–53. doi:10.1093/oxfordjournals.bmb.a074201.
   Google Scholar
• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(Suppl):D42–D50. doi:10.1016/j.jacc.2013.10.032.
   Google Scholar
• Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(Suppl 1):S5–S12. doi:10.1016/j.jacc.2004.02.037.
   Google Scholar
• Hambly N, Alawfi F, Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. CMAJ. 2016;188(11):804–2. doi:10.1503/cmaj.151075.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41. doi:10.1016/j.jacc.2013.10.029.
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–23. doi:10.7326/0003-4819-107-2-216.
   PubMed Web of Science ®Google Scholar
• Grieve AP, Chow SC, Curram J, et al. Advancing clinical trial design in pulmonary hypertension. Pulm Circ. 2013;3(1):217–25. doi:10.4103/2045-8932.109933.
   Google Scholar
• Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol. 2005;33:425–31. doi:10.1165/rcmb.F307.
   PubMedGoogle Scholar
• Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. Circulation. 1958;18:533–47. doi:10.1161/01.CIR.18.4.533.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Groves BM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275–85.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Archer SL, Dorfmuller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D4–12. doi:10.1016/j.jacc.2013.10.025.
   PubMed Web of Science ®Google Scholar
• Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101:927–34 doi:10.1172/JCI1910.
   PubMed Web of Science ®Google Scholar
• Ghigna MR, Guignabert C, Montani D, et al. BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J. 2016;48(6):1668–1681. doi:10.1183/13993003.00464-2016.
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358–63. doi:10.1183/09031936.03.00038903.
   PubMed Web of Science ®Google Scholar
• Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115(1):176–88. doi:10.1161/CIRCRESAHA.113.301129.
   PubMed Web of Science ®Google Scholar
• Vonk–Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62(25 Suppl):D22–33. doi:10.1016/j.jacc.2013.10.027.
   PubMed Web of Science ®Google Scholar
• van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511–9. doi:10.1016/j.jacc.2011.06.068.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22. doi:10.1016/S2213-2600(15)00543-3.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–30. doi:10.1164/rccm.200510-1668OC.
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104–9. doi:10.1183/09031936.00092306.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long–term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–456. doi:10.1378/chest.11-1460.
   PubMed Web of Science ®Google Scholar
• Thenappan T, Shah SJ, Rich S, et al. A USA–based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30(6):1103–10. doi:10.1183/09031936.00042107.
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–23. doi:10.7326/0003-4819-107-2-216.
   PubMed Web of Science ®Google Scholar
• Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non–US Contemporary Registries. Chest. 2011;139(1):128–37. Epub 2010 Jun 17. doi:10.1378/chest.10-0075.
   PubMed Web of Science ®Google Scholar
• Mehta S, Vachiéry JL. Pulmonary hypertension: the importance of correctly diagnosing the cause. Eur Respir Rev. 2016;25(142):372–80. doi:10.1183/16000617.0104-2016.
   Google Scholar
• Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871–80. doi:10.1016/j.ijcard.2012.10.026.
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9. doi:10.7326/0003-4819-115-5-343.
   PubMed Web of Science ®Google Scholar
• Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140(1):19–26.
   Google Scholar
• Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long–term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–56.
   PubMed Web of Science ®Google Scholar
• Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long–term survival. Arthritis Rheum. 2011;63(11):3522–30.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European respiratory society (ERS). Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. Primary pulmonary hypertension study group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan in pulmonary arterial hypertension, randomized, double–blind, placebo–controlled, multicenter, efficacy studies (ARIES) group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double–blind, placebo–controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin–receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo–controlled study. Lancet. 2001;358(9288):1119–23.
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil use in pulmonary arterial hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add–on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(6):632–43.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for pulmonary hypertension. N Engl J Med. 2013;369(23):2268.
   Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double–blind, randomized, placebo–controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4. doi:10.1164/ajrccm.165.6.2106079.
   PubMed Web of Science ®Google Scholar
• Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6–minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta–analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192–201. doi:10.1016/j.jacc.2012.01.083.
   PubMedGoogle Scholar
• Benza RL, Miller DP, Gomberg–Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long–term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164–72. doi:10.1161/CIRCULATIONAHA.109.898122.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S97–107. doi:10.1016/j.jacc.2009.04.007.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. doi:10.1056/NEJMoa1213917.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33. doi:10.1056/NEJMoa1503184.
   PubMed Web of Science ®Google Scholar
• Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102(6):1133–7. doi:10.1097/00000542-200506000-00012.
   PubMed Web of Science ®Google Scholar
• Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41(6):1302–7. doi:10.1183/09031936.00089212.
   Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014;129(1):57–65. doi:10.1161/CIRCULATIONAHA.113.004526.
   PubMed Web of Science ®Google Scholar
• Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long–term pah disease management (REVEAL). Circulation. 2015;132(25):2403–11. doi:10.1161/CIRCULATIONAHA.115.018435.
   PubMed Web of Science ®Google Scholar
• Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–44. doi:10.1056/NEJMoa1413687.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, et al. Long–term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–11. doi:10.1161/CIRCULATIONAHA.104.488486.
   PubMed Web of Science ®Google Scholar
• van de Veerdonk MC, Kind T, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511–9. doi:10.1016/j.jacc.2011.06.068.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691–7. doi:10.1183/09031936.00116313.
   PubMed Web of Science ®Google Scholar
• Perrin S, Chaumais MC, O'Connell C, et al. New pharmacotherapy options for pulmonary arterial hypertension. Expert Opin Pharmacother. 2015;16(14):2113–31. doi:10.1517/14656566.2015.1074177.
   PubMed Web of Science ®Google Scholar